Patrik Palacka, Jana Obertová
Bladder cancer is the most frequent malignant disease of urinary system with slowly increasing incidence. Neoadjuvant and/ or adjuvant chemotherapy in patients with muscle invasive bladder cancer is still discussed. The objective of the review is to analyse published clinical trials and formulate recommendations for clinical practitioners. On the basis of available data, neoadjuvant treatment with cisplatin is currently recommended in every patient with muscle invasive bladder cancer with planned cystectomy due to improved overall survival. Adjuvant chemotherapy is recommended to every patient after cystectomy for T3-T4 bladder cancer and/or positive lymphatic nodes. Another clinical trials should answer the question of optimal sequence neoadjuvant/adjuvant chemotherapy and surgical approach.